Experiments investigating the impact of BCAR1 and EREG on chemotherapy showed that reduction of BCAR1/p130Cas sensitizes CRC cells to FOLFIRI, whereas EREG had no effect itself and on p130Cas-mediated effects. The gene discussed is EREG; the disease is colorectal carcinoma.